US Food & Drug Administration (USFDA) has completed inspection at Alembic Pharmaceuticals’ Bioequivalence facility located at Vadodara. The agency had conducted inspection from August 12, 2019 to August 15, 2019 and from August 12, 2019 to August 20, 2019 for Bioequivalence Bioanalytical and Bioequivalence Clinical. There were no 483s issued by USFDA at the end of the inspection.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.
